TrialDiabetes, obesity & metabolism2025

The effect of the endothelin receptor antagonist atrasentan on insulin resistance in phenotypic clusters of patients with type 2 diabetes and chronic kidney disease.

Johannes David Smeijer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.